CoChat
Sign Up
Cited by 451

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

The ADAMs: signalling scissors in the tumour microenvironment

Murphy, Gillian·2008·Nature Reviews Cancer
DOI 10.1038/nrc2459
Open this paper in CoChat — free account

Abstract

Over the last few years disintegrin metalloproteinases of the Adam (a disintegrin and metalloproteinase) family have been associated with the process of proteolytic 'shedding' of membrane-associated proteins and hence the rapid modulation of key cell signalling pathways in the tumour microenvironment. Furthermore, numerous members of the Adam family have been associated with tumorigenesis and tumour progression. The question now arises of whether pharmacological manipulation of their functions would be a useful adjunct to therapies targeting intercellular communications. To learn from the lessons of matrix metalloproteinase inhibitors as anticancer agents, there are many facets of the biological and clinical relevance of the ADAMs that need to be understood before embarking with confidence on such an approach.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrc2459

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • ADAMs and MMPs are two prominent families of sheddases responsible for the shedding of single-span transmembrane proteins, such as LDLR.

    “A disintegrin and metalloproteinases (ADAMs) and matrix metalloproteinases (MMPs) are two prominent families of sheddases responsible for the shedding of single-span transmembrane proteins, such as LDLR (12).”

    From ADAM17 mediates ectodomain shedding of the soluble VLDL receptor fragment in the retinal epithelium (2021) · cites this paper as [12]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 136

  1. Coussens, L. M., Fingleton, B. & Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387–2392 (2002). The first major review documenting the problems of tackling metalloproteinases as therapeutic targets in cancer and the way forward. · DOI · Paper page
  2. Lopez-Otin, C. & Matrisian, L. M. Emerging roles of proteases in tumour suppression. Nature Rev. Cancer 7, 800–808 (2007). · DOI
  3. Stöcker, W. & Bode, W. Structural features of a superfamily of zinc-endopeptidases: the metzincins. Curr. Opin. Struct. Biol. 5, 383–390 (1995). · DOI
  4. Cuniasse, P. et al. Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs. Biochimie 87, 393–402 (2005). · DOI
  5. Singh, R. J. et al. Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3. Cardiovasc. Res. 67, 39–49 (2005). · DOI
  6. Lambert, D. W., Clarke, N. E., Hooper, N. M. & Turner, A. J. Calmodulin interacts with angiotensin-converting enzyme-2 (ACE2) and inhibits shedding of its ectodomain. FEBS Lett. 582, 385–390 (2008). · DOI
  7. Hart, S., Fischer, O. M. & Ullrich, A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor a-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res. 64, 1943–1950 (2004). · DOI
  8. Fox, J. W. & Serrano, S. M. Structural considerations of the snake venom metalloproteinases, key members of the M12 reprolysin family of metalloproteinases. Toxicon 45, 969–985 (2005). · DOI · Paper page
  9. Rocks, N. et al. Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie 90, 369–379 (2008). · DOI
  10. Cho, C., Primakoff, P., White, J. M. & Myles, D. G. Chromosomal assignment of four testis-expressed mouse genes from a new family of transmembrane proteins (ADAMs) involved in cell–cell adhesion and fusion. Genomics 34, 413–417 (1996). · DOI
  11. Mochizuki, S. & Okada, Y. ADAMs in cancer cell proliferation and progression. Cancer Sci. 98, 621–628 (2007). · DOI
  12. Garton, K. J., Gough, P. J. & Raines, E. W. Emerging roles for ectodomain shedding in the regulation of inflammatory responses. J. Leukoc. Biol. 79, 1105–1116 (2006). · DOI
  13. Holgate, S. T. et al. The genetics of asthma: ADAM33 as an example of a susceptibility gene. Proc. Am. Thorac. Soc. 3, 440–443 (2006). · DOI
  14. Gilpin, B. J. et al. A novel secreted form of human ADAM 12 (Meltrin a) provokes myogenesis in vivo. J. Biol. Chem. 273, 157–166 (1998). · DOI
  15. Powell, R. M., Wicks, J., Holloway, J. W., Holgate, S. T. & Davies, D. E. The splicing and fate of ADAM33 transcripts in primary human airways fibroblasts. Am. J. Respir. Cell. Mol. Biol. 31, 13–21 (2004). · DOI
  16. Mazzocca, A. et al. A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res. 65, 4728–4738 (2005). · DOI
  17. Blanchot-Jossic, F. et al. Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells. J. Pathol. 207, 156–163 (2005). · DOI
  18. Peduto, L. et al. ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression. Oncogene 25, 5462–5466 (2006). · DOI
  19. Kuefer, R. et al. ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease. Neoplasia 8, 319–329 (2006). · DOI
  20. Luo, J. et al. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res. 61, 4683–4688 (2001).
  21. McCulloch, D. R., Akl, P., Samaratunga, H., Herington, A. C. & Odorico, D. M. Expression of the disintegrin metalloprotease, ADAM-10, in prostate cancer and its regulation by dihydrotestosterone, insulin-like growth factor I, and epidermal growth factor in the prostate cancer cell model LNCaP. Clin. Cancer Res. 10, 314–323 (2004). · DOI
  22. Arima, T. et al. Nuclear translocation of ADAM-10 contributes to the pathogenesis and progression of human prostate cancer. Cancer Sci. (2007). · DOI
  23. Fritzsche, F. R. et al. ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur. Urol. 54, 1106–1107 (2007).
  24. Peduto, L., Reuter, V. E., Shaffer, D. R., Scher, H. I. & Blobel, C. P. Critical function for ADAM9 in mouse prostate cancer. Cancer Res. 65, 9312–9319 (2005). · DOI
  25. McGowan, P. M. et al. ADAM-17 predicts adverse outcome in patients with breast cancer. Ann. Oncol. 19, 1075–1081 (2008). · DOI
  26. Borrell-Pages, M., Rojo, F., Albanell, J., Baselga, J. & Arribas, J. TACE is required for the activation of the EGFR by TGF-α in tumors. EMBO J. 22, 1114–1124 (2003). · DOI
  27. O'Shea, C. et al. Expression of ADAM-9 mRNA and protein in human breast cancer. Int. J. Cancer 105, 754–761 (2003). · DOI
  28. Sjoblom, T. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268–274 (2006). · DOI
  29. Dyczynska, E., Syta, E., Sun, D. & Zolkiewska, A. Breast cancer-associated mutations in metalloprotease disintegrin ADAM12 interfere with the intracellular trafficking and processing of the protein. Int. J. Cancer 122, 2634–2640 (2008). · DOI
  30. Prenzel, N. et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402, 884–888 (1999). The first paper describing the role of a metalloproteinase activity in EGFR transactivation by GPCRs. · DOI
  31. Blobel, C. P. ADAMs: key components in EGFR signalling and development. Nature Rev. Mol. Cell. Biol. 6, 32–43 (2005). A summary of the most important findings on the ADAMs with roles in the regulation of EGFR signalling. · DOI
  32. Zheng, Y., Saftig, P., Hartmann, D. & Blobel, C. Evaluation of the contribution of different ADAMs to tumor necrosis factor α (TNFα) shedding and of the function of the TNFα ectodomain in ensuring selective stimulated shedding by the TNFα convertase (TACE/ADAM17). J. Biol. Chem. 279, 42898–42906 (2004). · DOI
  33. Balkwill, F. TNF-α in promotion and progression of cancer. Cancer Metastasis Rev. 25, 409–416 (2006). · DOI
  34. Schulte, M. et al. ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death. Cell Death Differ. 14, 1040–1049 (2007). · DOI
  35. Edwards, D. R., Handsley, M. M. & Pennington, C. J. The ADAM metalloproteinases. Mol. Aspects Med. 29, 258–259 (2008). The most up-to-date and comprehensive review of all aspects of ADAM biology and involvement in human diseases. · DOI
  36. Rose-John, S., Scheller, J., Elson, G. & Jones, S. A. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J. Leukoc. Biol. 80, 227–236 (2006). · DOI
  37. Garton, K. J. et al. Tumor necrosis factor-α-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J. Biol. Chem. 276, 37993–38001 (2001). · DOI
  38. Tousseyn, T., Jorissen, E., Reiss, K. & Hartmann, D. (Make) stick and cut loose — disintegrin metalloproteases in development and disease. Birth Defects Res. C Embryo Today 78, 24–46 (2006). · DOI
  39. White, J. M. ADAMs: modulators of cell–cell and cell–matrix interactions. Curr. Opin. Cell Biol. 15, 598–606 (2003). · DOI
  40. Reiss, K., Ludwig, A. & Saftig, P. Breaking up the tie: disintegrin-like metalloproteinases as regulators of cell migration in inflammation and invasion. Pharmacol. Ther. 111, 985–1006 (2006). · DOI
  41. Maretzky, T. et al. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and b-catenin translocation. Proc. Natl Acad. Sci. USA 102, 9182–9187 (2005). · DOI
  42. Waldhauer, I. et al. Tumor-associated MICA is shed by ADAM proteases. Cancer Res. 68, 6368–6376 (2008). · DOI
  43. Hakulinen, J. & Keski-Oja, J. ADAM10-mediated release of complement membrane cofactor protein during apoptosis of epithelial cells. J. Biol. Chem. 281, 21369–21376 (2006). · DOI
  44. Hynes, N. E. & Lane, H. A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Rev. Cancer 5, 341–354 (2005). This review highlights of the problems of targeting the Erbb receptors in cancer. · DOI
  45. Zhou, B. B. et al. ADAM proteases, ErbB pathways and cancer. Expert Opin. Investig. Drugs 14, 591–606 (2005). · DOI
  46. Revillion, F., Lhotellier, V., Hornez, L., Bonneterre, J. & Peyrat, J. P. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann. Oncol. 19, 73–80 (2008). · DOI
  47. Fridman, J. S. et al. Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clin. Cancer Res. 13, 1892–1902 (2007). · DOI
  48. Kenny, P. A. & Bissell, M. J. Targeting TACE-dependent EGFR ligand shedding in breast cancer. J. Clin. Invest. 117, 337–345 (2007). · DOI
  49. Liu, X. et al. Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab. Cancer Biol. Ther. 5, 648–656 (2006). · DOI
  50. Lafky, J. M., Wilken, J. A., Baron, A. T. & Maihle, N. J. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim. Biophys. Acta 1785, 232–265 (2008).
  51. Horiuchi, K. et al. Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Mol. Biol. Cell 18, 176–188 (2007). · DOI
  52. Schulte, A. et al. Sequential processing of the transmembrane chemokines CX3CL1 and CXCL16 by α- and γ-secretases. Biochem. Biophys. Res. Commun. 358, 233–240 (2007). · DOI
  53. Williams, C. C. et al. The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. J. Cell Biol. 167, 469–478 (2004). · DOI
  54. Selkoe, D. J. & Wolfe, M. S. Presenilin: running with scissors in the membrane. Cell 131, 215–221 (2007). This article details the current knowledge of the action of γ-secretases as co-regulators — with the ADAMs — of transmembrane protein signalling. · DOI
  55. Linggi, B. & Carpenter, G. ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol. 16, 649–656 (2006). · DOI
  56. Nanba, D. et al. An intermediary role of proHB-EGF shedding in growth factor-induced c-Myc gene expression. J. Cell Physiol. 214, 465–473 (2008). · DOI
  57. Shih Ie, M. & Wang, T. L. Notch signaling, γ-secretase inhibitors, and cancer therapy. Cancer Res. 67, 1879–1882 (2007). · DOI
  58. Murphy, G., Murthy, A. & Khokha, R. Clipping, shedding and RIPping keep immunity on cue. Trends Immunol. 29, 75–82 (2008). · DOI
  59. Schlondorff, J., Becherer, J. D. & Blobel, C. P. Intracellular maturation and localization of the tumour necrosis factor α convertase (TACE). Biochem. J. 347 (Pt 1), 131–138 (2000). · DOI
  60. Doedens, J. R. & Black, R. A. Stimulation-induced down-regulation of tumor necrosis factor-α converting enzyme. J. Biol. Chem. 275, 14598–14607 (2000). · DOI
  61. Becherer, J. D. & Blobel, C. P. Biochemical properties and functions of membrane-anchored metalloprotease-disintegrin proteins (ADAMs). Curr. Top. Dev. Biol. 54, 101–123 (2003). · DOI
  62. Zheng, Y., Schlondorff, J. & Blobel, C. P. Evidence for regulation of the tumor necrosis factor α-convertase (TACE) by protein-tyrosine phosphatase PTPH1. J. Biol. Chem. 277, 42463–42470 (2002). · DOI
  63. Mackay, H. J. & Twelves, C. J. Targeting the protein kinase C family: are we there yet? Nature Rev. Cancer 7, 554–562 (2007). · DOI
  64. Tonks, N. K. Protein tyrosine phosphatases: from genes, to function, to disease. Nature Rev. Mol. Cell Biol. 7, 833–846 (2006). · DOI
  65. Nagano, O. et al. Cell–matrix interaction via CD44 is independently regulated by different metalloproteinases activated in response to extracellular Ca2+ influx and PKC activation. J. Cell Biol. 165, 893–902 (2004). · DOI
  66. Soond, S. M., Everson, B., Riches, D. W. & Murphy, G. ERK-mediated phosphorylation of Thr735 in TNFα-converting enzyme and its potential role in TACE protein trafficking. J. Cell Sci. 118, 2371–2380 (2005). · DOI
  67. Ramsay, A. G., Marshall, J. F. & Hart, I. R. Integrin trafficking and its role in cancer metastasis. Cancer Metastasis Rev. 26, 567–578 (2007). · DOI
  68. Seals, D. F. & Courtneidge, S. A. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 17, 7–30 (2003). · DOI
  69. Izumi, Y. et al. A metalloprotease-disintegrin, MDC9/meltrin-γ/ADAM9 and PKCδ are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J. 17, 7260–7272 (1998). · DOI
  70. Sanderson, M. P. et al. ADAM10 mediates ectodomain shedding of the betacellulin precursor activated by p-aminophenylmercuric acetate and extracellular calcium influx. J. Biol. Chem. 280, 1826–1837 (2005). · DOI
  71. Stoeck, A. et al. A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. Biochem. J. 393, 609–618 (2006). · DOI
  72. Skovronsky, D. M., Pijak, D. S., Doms, R. W. & Lee, V. M. A distinct ER/IC γ-secretase competes with the proteasome for cleavage of APP. Biochemistry 39, 810–817 (2000). · DOI
  73. Shirakabe, K., Wakatsuki, S., Kurisaki, T. & Fujisawa-Sehara, A. Roles of Meltrin β /ADAM19 in the processing of neuregulin. J. Biol. Chem. 276, 9352–9358 (2001). · DOI
  74. Yokozeki, T. et al. Meltrin β (ADAM19) mediates ectodomain shedding of Neuregulin β1 in the Golgi apparatus: fluorescence correlation spectroscopic observation of the dynamics of ectodomain shedding in living cells. Genes Cells 12, 329–343 (2007). · DOI
  75. Matthews, V. et al. Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J. Biol. Chem. 278, 38829–38839 (2003). · DOI · Paper page
  76. Wild-Bode, C., Fellerer, K., Kugler, J., Haass, C. & Capell, A. A basolateral sorting signal directs ADAM10 to adherens junctions and is required for its function in cell migration. J. Biol. Chem. 281, 23824–23829 (2006). · DOI
  77. Smalley, D. M. & Ley, K. L-selectin: mechanisms and physiological significance of ectodomain cleavage. J. Cell. Mol. Med. 9, 255–266 (2005). · DOI
  78. Kaiser, B. K. et al. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 447, 482–486 (2007). · DOI
  79. Cui, X. et al. Identification of ARTS-1 as a novel TNFR1-binding protein that promotes TNFR1 ectodomain shedding. J. Clin. Invest. 110, 515–526 (2002). · DOI
  80. Nishi, E., Hiraoka, Y., Yoshida, K., Okawa, K. & Kita, T. Nardilysin enhances ectodomain shedding of heparin-binding epidermal growth factor-like growth factor through activation of tumor necrosis factor-α-converting enzyme. J. Biol. Chem. 281, 31164–31172 (2006). · DOI
  81. Gechtman, Z., Alonso, J. L., Raab, G., Ingber, D. E. & Klagsbrun, M. The shedding of membrane-anchored heparin-binding epidermal-like growth factor is regulated by the Raf/mitogen-activated protein kinase cascade and by cell adhesion and spreading. J. Biol.Chem. 274, 28828–28835 (1999). · DOI
  82. Yan, Y., Shirakabe, K. & Werb, Z. The metalloprotease Kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G protein-coupled receptors. J. Cell Biol. 158, 221–226 (2002). · DOI
  83. Le Naour, F. et al. Profiling of the tetraspanin web of human colon cancer cells. Mol. Cell Proteomics 5, 845–857 (2006). · DOI
  84. Clevers, H. & Batlle, E. EphB/EphrinB receptors and Wnt signaling in colorectal cancer. Cancer Res. 66, 2–5 (2006). · DOI
  85. Janes, P. W., Adikari, S. & Lackmann, M. Eph/ephrin signalling and function in oncogenesis: lessons from embryonic development. Curr. Cancer Drug Targets. 8, 473–479 (2008). · DOI
  86. Himanen, J. P., Saha, N. & Nikolov, D. B. Cell–cell signaling via Eph receptors and ephrins. Curr. Opin. Cell Biol. 19, 534–542 (2007). · DOI
  87. Bray, S. J. Notch signalling: a simple pathway becomes complex. Nature Rev. Mol. Cell Biol. 7, 678–689 (2006). · DOI · Paper page
  88. Ohtsu, H., Dempsey, P. J. & Eguchi, S. ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am. J. Physiol. Cell Physiol. 291, C1–C10 (2006). · DOI
  89. Hart, S. et al. GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways. Biol. Chem. 386, 845–855 (2005). · DOI
  90. Song, R. X., Zhang, Z., Chen, Y., Bao, Y. & Santen, R. J. Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. Endocrinology 148, 4091–4101 (2007). · DOI
  91. Civenni, G., Holbro, T. & Hynes, N. E. Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells. EMBO Rep. 4, 166–171 (2003). · DOI
  92. Faivre, E. J. & Lange, C. A. Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Mol. Cell. Biol. 27, 466–480 (2007). · DOI
  93. Marin, V. et al. Chemotactic agents induce IL-6Rα shedding from polymorphonuclear cells: involvement of a metalloproteinase of the TNF-α-converting enzyme (TACE) type. Eur. J. Immunol. 32, 2965–2970 (2002). · DOI
  94. Baker, A. H., Edwards, D. R. & Murphy, G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell Sci. 115, 3719–3727 (2002). · DOI
  95. Nagase, H., Visse, R. & Murphy, G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 69, 562–573 (2006). · DOI
  96. Smookler, D. S. et al. Cutting edge: tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. J. Immunol. 176, 721–725 (2006). · DOI
  97. Cruz-Munoz, W., Kim, I. & Khokha, R. TIMP-3 deficiency in the host, but not in the tumor, enhances tumor growth and angiogenesis. Oncogene (2005). · DOI
  98. Hoque, M. O. et al. Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer. J. Urol. 179, 743–747 (2008). · DOI
  99. Kopitz, C. et al. Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res. 67, 8615–8623 (2007). · DOI
  100. Moss, M. L., Sklair-Tavron, L. & Nudelman, R. Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nature Clin. Pract. Rheumatol. 4, 300–309 (2008). · DOI
  101. Zhou, B. B. et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 10, 39–50 (2006). · DOI
  102. Moss, M. L., Stoeck, A., Yan, W. & Dempsey, P. J. ADAM10 as a target for anti-cancer therapy. Curr. Pharm. Biotechnol. 9, 2–8 (2008). · DOI
  103. Hojilla, C. V., Wood, G. A. & Khokha, R. Inflammation and breast cancer. metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancer. Breast Cancer Res. 10, 205 (2008). · DOI
  104. Lee, M. H. et al. Engineering N-terminal domain of tissue inhibitor of metalloproteinase (TIMP)-3 to be a better inhibitor against tumour necrosis factor-α- converting enzyme. Biochem. J. 364, 227–234 (2002). · DOI
  105. D'Abaco, G. M. et al. ADAM22, expressed in normal brain but not in high-grade gliomas, inhibits cellular proliferation via the disintegrin domain. Neurosurgery 58, 179–186; discussion 179–186 (2006). · DOI
  106. Takada, H. et al. ADAM23, a possible tumor suppressor gene, is frequently silenced in gastric cancers by homozygous deletion or aberrant promoter hypermethylation. Oncogene 24, 8051–8060 (2005). · DOI
  107. Moss, M. L., White, J. M., Lambert, M. H. & Andrews, R. C. TACE and other ADAM proteases as targets for drug discovery. Drug Discov. Today 6, 417–426 (2001). The whys and wherefores of recent approaches to the inhibition of ADAM catalytic activities as potential disease therapies. · DOI
  108. Shah, B. H. & Catt, K. J. TACE-dependent EGF receptor activation in angiotensin-II-induced kidney disease. Trends Pharmacol. Sci. 27, 235–237 (2006). · DOI
  109. Postina, R. A closer look at α-secretase. Curr. Alzheimer Res. 5, 179–186 (2008). · DOI
  110. Camden, J. M. et al. P2Y2 nucleotide receptors enhance α-secretase-dependent amyloid precursor protein processing. J. Biol. Chem. 280, 18696–18702 (2005). · DOI
  111. Buckley, C. A. et al. Amino-terminal TACE prodomain attenuates TNFR2 cleavage independently of the cysteine switch. Am. J. Physiol. Lung Cell. Mol. Physiol. 288, L1132–1138 (2005). · DOI
  112. Janes, P. W. et al. Adam meets Eph: an ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Cell 123, 291–304 (2005). · DOI
  113. Serrano, S. M., Jia, L. G., Wang, D., Shannon, J. D. & Fox, J. W. Function of the cysteine-rich domain of the haemorrhagic metalloproteinase atrolysin A: targeting adhesion proteins collagen I and von Willebrand factor. Biochem. J. 391, 69–76 (2005). · DOI
  114. Smith, K. M. et al. The cysteine-rich domain regulates ADAM protease function in vivo. J. Cell Biol. 159, 893–902 (2002). · DOI
  115. Reddy, P. et al. Functional analysis of the domain structure of tumor necrosis factor-α converting enzyme. J. Biol.Chem. 275, 14608–14614 (2000). · DOI
  116. Abram, C. L. et al. The adaptor protein fish associates with members of the ADAMs family and localizes to podosomes of Src-transformed cells. J. Biol. Chem. 278, 16844–16851 (2003). · DOI
  117. Tanaka, M. et al. ADAM binding protein Eve-1 is required for ectodomain shedding of epidermal growth factor receptor ligands. J. Biol. Chem. 279, 41950–41959 (2004). · DOI
  118. Wildeboer, D., Naus, S., Amy Sang, Q. X., Bartsch, J. W. & Pagenstecher, A. Metalloproteinase disintegrins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activities are associated with invasiveness. J. Neuropathol. Exp. Neurol. 65, 516–527 (2006). · DOI
  119. Roemer, A. et al. Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome. Oncol. Rep. 11, 529–536 (2004).
  120. Ishikawa, N. et al. ADAM8 as a novel serological and histochemical marker for lung cancer. Clin. Cancer Res. 10, 8363–8370 (2004). · DOI
  121. Valkovskaya, N. et al. ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer. J. Cell. Mol. Med. 11, 1162–1174 (2007). · DOI
  122. Carl-McGrath, S., Lendeckel, U., Ebert, M., Roessner, A. & Rocken, C. The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int. J. Oncol. 26, 17–24 (2005).
  123. Shintani, Y. et al. Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis. Cancer Res. 64, 4190–4196 (2004). · DOI
  124. Grutzmann, R. et al. ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br. J. Cancer 90, 1053–1058 (2004). · DOI
  125. Gavert, N. et al. L1, a novel target of β-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J. Cell Biol. 168, 633–642 (2005). · DOI
  126. Yoshimura, T. et al. ADAMs (a disintegrin and metalloproteinase) messenger RNA expression in Helicobacter pylori-infected, normal, and neoplastic gastric mucosa. J. Infect. Dis. 185, 332–340 (2002). · DOI
  127. Fogel, M. et al. L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet 362, 869–875 (2003). · DOI
  128. Roy, R., Wewer, U. M., Zurakowski, D., Pories, S. E. & Moses, M. A. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J. Biol. Chem. 279, 51323–51330 (2004). · DOI
  129. Kodama, T. et al. ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. Am. J. Pathol. 165, 1743–1753 (2004). · DOI
  130. Le Pabic, H. et al. ADAM12 in human liver cancers: TGF-β-regulated expression in stellate cells is associated with matrix remodeling. Hepatology 37, 1056–1066 (2003). · DOI
  131. Lendeckel, U. et al. Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J. Cancer Res. Clin. Oncol. 131, 41–48 (2005). · DOI
  132. Schutz, A. et al. Expression of ADAM15 in lung carcinomas. Virchows Arch. 446, 421–429 (2005). · DOI
  133. Karan, D. et al. Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas. Int. J. Oncol. 23, 1365–1371 (2003).
  134. Zheng, X. et al. Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness. Cancer Sci. 98, 674–684 (2007). · DOI
  135. Mitsui, Y. et al. ADAM28 is overexpressed in human breast carcinomas: implications for carcinoma cell proliferation through cleavage of insulin-like growth factor binding protein-3. Cancer Res. 66, 9913–9920 (2006). · DOI
  136. Ohtsuka, T. et al. ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis. Int. J. Cancer 118, 263–273 (2006). · DOI

Cited by

Sorted by citations

Metadata

Authors
Murphy, G.
Venue
Nature Reviews Cancer
Publisher
Springer Science and Business Media LLC
Published
2008-11-13
Volume
8
Issue
12
Pages
932-941
ISSN
  • 1474-175X
  • 1474-1768
DOI
10.1038/nrc2459
Cited by
451
References
3
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review